TABLE 1.
Pharmacodynamic parameters estimated for DOX, SFB, and 5-FU as combined with let-7c or control MSA in the inhibition of Hep3B cell viability
| MSA | Let-7c | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.0 nM | 2.5 nM | 1.0 nM | 2.5 nM | ||||||||||
| EC50 | DOX (nM) | 230.3 | ± | 1.1 | 240.2 | ± | 1.1 | 205.9 | ± | 1.1 | 230.2 | ± | 1.2 |
| SFB (µM) | 4.8 | ± | 1.1 | 5.2 | ± | 1.0 | 4.9 | ± | 1.0 | 5.2 | ± | 1.0 | |
| 5-FU (µM) | 237.2 | ± | 1.3 | 132.6 | ± | 1.7 | 56.9 | ± | 1.9* | 2.4 | ± | 3.4* | |
| Emin | DOX (nM) | 1.7 | ± | 1.6 | >0.05 | 14.2 | ± | 1.1* | 43.2 | ± | 1.1* | ||
| SFB (µM) | 8.4 | ± | 1.5 | 3.8 | ± | 0.7 | 12.0 | ± | 1.0 | 31.7 | ± | 1.0* | |
| 5-FU (µM) | 7.2 | ± | 2.9 | 14.1 | ± | 4.3 | 9.9 | ± | 5.6 | 33.5 | ± | 8.0* | |
| Hill slope | DOX | 1.4 | ± | 0.2 | 1.6 | ± | 0.2 | 1.6 | ± | 0.2 | 1.6 | ± | 0.2 |
| SFB | 2.8 | ± | 0.4 | 2.9 | ± | 0.1 | 2.5 | ± | 0.2 | 2.4 | ± | 0.3 | |
| 5-FU | 0.8 | ± | 0.1 | 0.4 | ± | 0.1 | 0.3 | ± | 0.1 | 0.3 | ± | 0.1 | |
| R2 | DOX | 0.98 | 0.99 | 0.99 | 0.98 | ||||||||
| SFB | 0.99 | 0.99 | 0.99 | 0.99 | |||||||||
| 5-FU | 0.96 | 0.91 | 0.92 | 0.94 | |||||||||
*
P < 0.05 compared with corresponding MSA control treatment.